By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AmextaFinanceAmextaFinance
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
AmextaFinanceAmextaFinance
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
AmextaFinance > Markets > Stocks > Goldman, JPMorgan, Morgan Stanley, UBS in $499 million stock lending settlement
Stocks

Goldman, JPMorgan, Morgan Stanley, UBS in $499 million stock lending settlement

News Room
Last updated: 2023/08/25 at 3:50 AM
By News Room
Share
3 Min Read
SHARE

© Reuters. FILE PHOTO-A logo of Swiss bank UBS is seen in Zurich, Switzerland March 29, 2023. REUTERS/Denis Balibouse/File Photo

By Jonathan Stempel

NEW YORK (Reuters) -Goldman Sachs, JPMorgan Chase (NYSE:), Morgan Stanley and UBS have agreed to pay $499 million to settle an antitrust lawsuit by investors who accused them of conspiring to stifle competition in the stock lending market.

The settlement was disclosed on Wednesday in a filing in Manhattan federal court.

It requires a judge’s approval, and also mandates governance changes at EquiLend, a joint venture among the defendants.

Led by four pension funds and a trading firm, the plaintiffs accused the banks of having conspired since 2009 to relegate the stock lending market to “the stone age” by boycotting startup platforms.

They said the banks did this by using their positions on EquiLend’s board to maintain monopoly control over the market, and charge excessive fees to investors.

Investors have now reached $580 million of settlements with five banks, including an $81 million accord in Feb. 2022 with Credit Suisse, which UBS bought in June.

The banks denied wrongdoing but settled to avoid the risk, cost and inconvenience of further litigation, court papers show.

They also agreed to cooperate in the investors’ case against the final defendant, Bank of America. The lawsuit began in Aug. 2017.

Spokespeople for Bank of America and UBS declined to comment. The other banks did not immediately respond to requests for comment.

The U.S. Department of the Treasury’s Financial Stability Oversight Council has estimated that $3.1 trillion of securities were on loan worldwide as of Sept. 2021.

EquiLend’s governance changes include new restrictions on how board members share information, and limits on how many board seats each bank can hold.

They also include a requirement that the board’s outside antitrust lawyers be “rotated” every three years, to avoid what the investors call the “capture” of those lawyers.

The case is Iowa Public Employees’ Retirement System et al v Bank of America Corp (NYSE:) et al, U.S. District Court, Southern District of New York, No. 17-06221.

Read the full article here

News Room August 25, 2023 August 25, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Worthington Enterprises: Upgrade To Buy On Improved Fundamentals (NYSE:WOR)

This article was written byFollowI focus on long-term investments while incorporating short-term…

EU will lose ‘race to the bottom’ on regulation, says competition chief

Stay informed with free updatesSimply sign up to the EU business regulation…

Why beef prices are soaring

Watch full video on YouTube

Opendoor is an AI stock: Analyst

Watch full video on YouTube

Sanofi-Dynavax: A Conservative Vaccine Deal With Upside Tail Risk (NASDAQ:SNY)

This article was written byFollowWith a background as a RN, I analyze…

- Advertisement -
Ad imageAd image

You Might Also Like

Stocks

CPS reports solid 2023 performance, eyes future growth By Investing.com

By News Room
Stocks

Niu Technologies faces mixed results in Q4 2023 By Investing.com

By News Room
Stocks

Exagen Inc. reports strong 2023 revenue growth By Investing.com

By News Room
Stocks

Legacy Housing reports mixed results amid sales decline By Investing.com

By News Room
Stocks

Harmony Biosciences exec sells over $383k in stock By Investing.com

By News Room
Stocks

Biofrontera posts record revenue and outlines growth plans By Investing.com

By News Room
Stocks

Granite Ridge CFO buys $31,000 in company stock By Investing.com

By News Room
Stocks

Coliseum Capital Management buys MasterCraft Boat shares worth over $3.2m By Investing.com

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

YOUR EMAIL HAS BEEN CONFIRMED.
THANK YOU!

Welcome Back!

Sign in to your account

Lost your password?